West Pharmaceutical can be ‘$370 stock’ in bull case, says Evercore ISI

Evercore ISI analyst Daniel Markowitz notes that West Pharmaceutical (WST) shares are down 30% since the company reported Q4 results, but believes that the bull case “remains intact” and argues “there were actually some positive datapoints on the Q4 call” with regard to the high-value components business. The firm, which lays out a “bull case” scenario where the stock could be valued at $370 per share, maintains an Outperform rating and $275 price target on West.